Coordinatore | THE UNIVERSITY OF MANCHESTER
Organization address
address: OXFORD ROAD contact info |
Nazionalità Coordinatore | United Kingdom [UK] |
Totale costo | 15˙727˙548 € |
EC contributo | 11˙999˙998 € |
Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
Code Call | FP7-HEALTH-2012-INNOVATION-1 |
Funding Scheme | CP-IP |
Anno di inizio | 2012 |
Periodo (anno-mese-giorno) | 2012-12-01 - 2017-11-30 |
# | ||||
---|---|---|---|---|
1 |
THE UNIVERSITY OF MANCHESTER
Organization address
address: OXFORD ROAD contact info |
UK (MANCHESTER) | coordinator | 3˙462˙748.00 |
2 |
CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL
Organization address
address: OLSHAUSENSTRASSE 40 contact info |
DE (KIEL) | participant | 1˙493˙400.00 |
3 |
UNIVERSITEIT MAASTRICHT
Organization address
address: Minderbroedersberg 4-6 contact info |
NL (MAASTRICHT) | participant | 995˙434.00 |
4 |
UNIVERSITAETSKLINIKUM AACHEN
Organization address
address: Pauwelsstrasse 30 contact info |
DE (AACHEN) | participant | 994˙800.00 |
5 |
THE UNIVERSITY OF LIVERPOOL
Organization address
address: Brownlow Hill, Foundation Building 765 contact info |
UK (LIVERPOOL) | participant | 992˙250.00 |
6 |
THE UNIVERSITY OF WARWICK
Organization address
address: Kirby Corner Road - University House - contact info |
UK (COVENTRY) | participant | 942˙410.00 |
7 |
DEUTSCHES KREBSFORSCHUNGSZENTRUM
Organization address
address: Im Neuenheimer Feld 280 contact info |
DE (HEIDELBERG) | participant | 849˙997.00 |
8 |
THE HEBREW UNIVERSITY OF JERUSALEM.
Organization address
address: GIVAT RAM CAMPUS contact info |
IL (JERUSALEM) | participant | 749˙999.00 |
9 |
GABO:MI GESELLSCHAFT FUR ABLAUFORGANISATION:MILLIARIUM MBH & CO KG GAB O
Organization address
address: Oskar-von-Miller-Ring 29 contact info |
DE (MUENCHEN) | participant | 501˙000.00 |
10 |
LIFEGLIMMER GMBH
Organization address
address: MARKELSTRASSE 39 A contact info |
DE (BERLIN) | participant | 500˙000.00 |
11 |
GENEXPLAIN GMBH
Organization address
address: AM EXER 10 B contact info |
DE (WOLFENBUTTEL) | participant | 499˙960.00 |
12 |
THE UNIVERSITY OF AUCKLAND
Organization address
address: PRINCES STREET 24 contact info |
NZ (AUCKLAND) | participant | 18˙000.00 |
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
'Inflammatory bowel disease (IBD) is a major health problem with severe co-morbidities, requiring life-long treatment. Oscillating processes, like biological clocks are well studied and modeled in a number of systems. Circadian rhythms are extremely important for optimal treatments of patients. Recently, the NfkB pathway has been shown to be oscillating. In this project, we will model NfkB oscillation in chronic inflammatory bowel diseases in animal models and patient cohorts with immunosuppressive treatments and controls. The aim is to build an experimentally validated model the NfkB oscillation in 4D within the gut tissue. Dynamic, experimental validation will be done for various types of cells in the gut by a combination of methods, including single-cell based transcriptomics, multi-photon microscopy and time-dependent, multi-component profiling. The validated model framework will enable searching for critical components of the Nfï«B oscillation and to assess their relevance for the disease in patients. Interfering with the oscillation of biological pathways may provide new possibilities to influence biological processes like inflammation. Hence, we will search (assisted by the models and databases developed) for small molecules interfering with the NfkB oscillation in chemical databases and validate selected candidates in experimental systems. To this end, we will use cell lines with the correct indicator constructs using high content microscopy. To better translate the findings in animal models to patients, we will use a mouse model with transplanted human tissue so that we can verify the mathematical model in human tissue and verify functionality of small molecules in vivo. Owing to its systems, highly focused approach, the project will generate substantial insights into key mechanisms underlying IBD and will provide ways to modulate the oscillatory behavior of the Nfï«B in IBD and IBD-dependent co-morbidities.'
European experts in the field of clinical and experimental immunology are studying NF-kappa-B signalling dynamics and oscillations in inflammatory bowel disease (IBD). The long-term goal is to identify biomarkers that could be exploited for disease prediction, diagnosis and stratification.